Is it time to combine untargeted antifungal strategies to reach the goal of &apos;early&apos; effective treatment? by Cortegiani, A. et al.
LETTER Open Access
Is it time to combine untargeted antifungal
strategies to reach the goal of ‘early’
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A recently published retrospective study by Posteraro et
al. [1] investigated the use of (1–3)-β-D-glucan (BDG) as
a strategy for antifungal drug administration in patients
at high risk of candidemia. The strategy consisted of the
administration of antifungals (anidulafungin in most
cases) to septic patients with a Candida score ≥ 3 and a
positive BDG result (≥80 pg/ml). This untargeted strat-
egy led to better selection of patients, avoiding exposure
to antifungals in approximately 73 % of patients with
negative BDG results and leading to shortened treatment
duration in another 20 % of patients.
Untargeted antifungal treatments (including prophy-
laxis, pre-emptive and empiric approaches) are the main-
stay of early invasive fungal infection (IFI) management
[2]. We recently published a Cochrane systematic review
investigating the effects of untargeted antifungal treatment
in terms of mortality and incidence of IFI in non-
neutropenic critically ill patients [3]. Notably, prophylaxis
resulted in IFI reduction but it may lead to exposure to
antifungals for an unacceptably high proportion of
patients, with associated potential adverse effects of
antifungals, increased risk of resistance and costs. On the
contrary, empiric treatment showed no benefit in terms of
IFI reduction and mortality. We hypothesized that this
observation may be due to inclusion of patients with a
more advanced disease stage [4]. Moreover, many patients
receiving antifungals may not need them, leading to the
observed lack of benefit. The pre-emptive strategy was less
investigated, with only one published randomized con-
trolled study included in the systematic review.
According to the findings of Posteraro et al. [1], a
surrogate marker-driven strategy, in association with risk
factors, might represent an adequate and cost-effective
approach to tailor antifungal treatment to patients who
may benefit most. Is it time to abandon classic antifun-
gal treatments to shift towards more pliant ‘early’ anti-
fungal strategies based on risk factors and biomarkers?
Data from non-randomized studies suggested that this
kind of antifungal strategy might combine advantages of
classic treatments with improved selection of patients
and reduced exposure to antifungals, also being able to
help clinicians to decide when to stop treatments [5].
There is a need for further randomized trials to answer
the question of whether surrogate marker/risk factor-
based antifungal strategies could be beneficial to our
critically ill patients, in comparison with other (old?)
untargeted treatments, in terms of efficacy, exposure to
antifungals and costs.
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